Treatment.com AI Announces Release of New Medical Education Suite (MES) and Update on the AI Assessment Symposium 1st November, 2024
Treatment.com AI announces expanded and updated MES new releases Lead commercial participant at Global/North American Symposium on AI Assessment in Medical Education Further enhancements and solutions set for H2 2024 VANCOUVER, British Columbia, November 4th, 2024 – Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (“Treatment”) is pleased to announce the launch of its updated Medical Education Suite (MES) to coincide withTreatment’s participation in a landmark Symposium on AI Assessment in Medical Education being hosted by the University of Minnesota Medical School on 1st November 2024. Medical Education Suite (MES) Release and Update It is estimated that over 80 countries globally have now adopted the OSCE (Objective Structured Clinical Examination) for assessing the practical clinical skills of medical students. It is estimated that between 200,000 and 300,000 medical students globally take the OSCE exam each year, as derived from indicative numbers of students from key professional bodies including: https://www.aamc.org/; https://www.uems.eu/; https://www.nmc.org.in/; Education – GMC (gmc-uk.org) As announced in a previous 2024 Press Releases,Treatment has been working diligently through 2024 to further evolve the Medical Education Suite (MES), powered by its proprietary Global Library of Medicine (GLM). The goal of furthering enhancements to the platform is the recognition that AI can be used even more effectively to reduce the administrative overhead and costs to schools in running OSCEs, as well providing greater support to medical students, thereby helping to optimize their clinical reasoning skills. Treatment’s service comprises of using its Global Library of Medicine platform (GLM) in (i) creating cases for the OSCE exams (ii) producing scripts for actors playing the role of patients (iii) scoring the exams with our proprietary automated marking platform and (iv) providing instant results to both faculty and students, as well as offering student enrichment plans. As part of this Release, Treatment is announcing the following additions to its portfolio: AI Patient – utilizing AI and a library of test Cases to further support students in their preparation and readiness for medical multiple-choice questions (MCQ’s) and OSCE exams. Objective Structured Clinical Examination (OSCE) Case Packages – the company is extending the number of test Cases provided from an initial 12 cases. These will be available in packs to schools and a planned library of up to 100 cases through Q4 2024. AI Prep Tool – the platform provides students with both a “guided” and “non-guided” support to learning. The “guided” approach provides students with learning support and reasoning, whereas the “non-guided” supports enables students to simulate exam conditions. Symposium on AI Assessment in Medical Education Together with the launch of its updated Medical Education Suite, Treatment is a lead participant in a Symposium on AI Assessment in Medical Education held on November 1, 2024 at the University of Minnesota Medical School, Office of Assessment and Evaluation. The creator of the Symposium, Dr. Claudio Violato described the event as a “landmark symposium”. (https://medtest.umn.edu/events) This academic Symposium includes more than fifty medical schools, thought leaders and national education examiners from across the US, as well as international representation. Presenters include Mayo Clinic, University of Alberta as well as Treatment’s Chief Medical Officer Kevin Peterson, MD, MPH, who will be a keynote speaker, as an acknowledged leader in medical education and its utilization of AI. Further enhancements and solutions for H2 2024 Treatment will continue to build out its Medical Education Suite through the rest of 2024 and early 2025. Further planned developments include: AI Doctor in a Pocket – delivers a mobile friendly AI powered clinical decision support tool for healthcare professionals and students when they are in clinics, residency or on a hospital ward. Audio/Video Analysis – using AI and the Global Library of Medicine to undertake Audio/Visual analysis which captures and transcribes the patient assessment. In addition, this will allow for behavioral analysis as part of exam scoring, as well as supporting the generation of a medical note. Dr. Essam Hamza, CEO of Treatment.com AI, comments: “We are excited to showcase our updated Medical Education Software Suite at this landmark Symposium. The opportunity to have a positive impact on the medical training of students and in turn introduce them to our range of proprietary AI tools is an important inflection point in the company’s commercialization timeline. We look forward to updating the market further in the near future. About Treatment.com AI Inc. Treatment.com AI is a company utilizing AI and best clinical practices to positively disrupt the healthcare sector and impact current inefficiencies and challenges. With the input of hundreds of healthcare professionals globally, Treatment has built a comprehensive, personalized healthcare AI engine, the Global Library of Medicine (GLM). Providing highly qualified clinical information and support to all healthcare professionals, as well as providing recommended tests (physical and lab), x-rays, and billing codes. The GLM helps healthcare professionals (doctor, nurse or pharmacist) reduce their administrative burden; create more time for needed face to face patient appointments and has the propensity for greater consistency in quality of patient support. Treatment’s GLM platform also brings the possibility of health equity and inclusion for disenfranchised communities. To learn more about Treatment’s products and services: www.treatment.com or email: info@treatment.com FOR ADDITIONAL INFORMATION, CONTACT: Dr. Essam Hamza, CEO ehamza@treatment.com For media inquiries, contact: media@treatment.com Call: +1 (612) 788-8900 / Toll-Free USA/Canada: +1 (888) 788-8955 Cautionary Statements This news release contains forward-looking statements that are based on Treatment.com AI’s expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to the implementation of its shareholder communications initiative and the timing thereof. Although Treatment.com believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements, and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and Treatment.com undertakes no obligation to update
Treatment.com Ai Inc. Closes Over-subscribed Non- Brokered Private Placement Of $1,954,074
Not for distribution to United States newswire services or for release publication, distribution, or dissemination directly, or indirectly, in whole or in part, in or into the United States. Vancouver, British Columbia, October 25, 2024 – Treatment.com AI Inc. (the “Company” or “Treatment”) (CSE: TRUE; OTC: TREIF; FFA: 939) is pleased to announce that, further to its news release dated October 4, 2024, it has closed a non-brokered private placement of 2,138,766 special warrants of the Company (each, a “Special Warrant”) at a price of $0.75 per Special Warrant, for aggregate gross proceeds of $1,604,074.50 and 466,666 units of the Company (each, a “Unit”) at a price of $0.75 per Unit, for aggregate gross proceeds of $349,999.50 (the “Offering”). Each Unit is comprised of one common share of the Company (each, a “Share”) and one-half of one Share purchase warrant (each whole warrant being, a “Warrant“) of the Company, with each Warrant exercisable into one Share at an exercise price of $1.00 for two (2) years from the date of issuance. Each Special Warrant will automatically convert, for no additional consideration, into one Unit on the date (the “Conversion Date”) that is the earlier of: (i) the third business day after the date of filing a prospectus supplement to a short form base shelf prospectus (the “Prospectus Supplement”) qualifying the distribution of the Shares and Warrants issuable upon the conversion of the Special Warrants, and (ii) 4 months and one day after the issue date of the Special Warrants. No Special Warrants may be exercised by the holder thereof prior to the Conversion Date Dr. Essam Hamza, CEO of the Company, stated: “We are very encouraged by the support from our investors with their overwhelming response to the financing and the subsequent over-subscription. This money will help expedite our aggressive growth plans over the next year.” In connection with the Offering, the Company has paid finder’s fees totalling $117,284 and issued an aggregate of 156,378 non-transferable broker warrants (the “Broker Warrants”) to arm’s-length parties. Each Broker Warrant entitles the holder to purchase one Share at an exercise price of $1.00 per Share for a period of two (2) years from the date of closing. The Company intends to use the proceeds raised from the Offering for working capital purposes. Prior to the filing of a Prospectus Supplement, the Special Warrants and the securities issuable upon conversion of the Special Warrants are subject to a statutory hold period of four months plus one day from the date of issuance in accordance with applicable securities legislation. The Units issued today and the Broker Warrants are subject to a statutory hold period of four months plus one day from the date of issuance in accordance with applicable securities legislation. The Special Warrants and Warrants will not be listed on any stock exchange or over-the-counter market. The securities issued pursuant to the Offering have not, nor will they be registered under the United States Securities Act of 1933, as amended, and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons in the absence of U.S. registration or an applicable exemption from the U.S. registration requirements. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or in any other jurisdiction in which such offer, solicitation or sale would be unlawful. About Treatment.com AI Inc. Treatment.com AI is a company utilizing AI and best clinical practices to positively improve the healthcare sector and impact current inefficiencies and challenges. With the input of hundreds of healthcare professionals globally, Treatment has built a comprehensive, personalized healthcare AI engine, the Global Library of Medicine (GLM). With more than ~10,000 expert medical reviews, the GLM delivers tested clinical information and support to all healthcare professionals, as well as providing recommended tests (physical and lab), x-rays, and billing codes. The GLM helps healthcare professionals (doctor, nurse or pharmacist) reduce their administrative burden; create more time for needed face to face patient appointments and enables greater consistency in quality of patient support. Treatment’s GLM platform, through supporting healthcare professionals, allows for the inclusion of disenfranchised communities. To learn more about Treatment’s products and services: www.treatment.com or email: info@treatment.com FOR ADDITIONAL INFORMATION, CONTACT: Dr. Essam Hamza, CEO ehamza@treatment.com For media inquiries, contact: media@treatment.com Call: +1 (612) 788-8900 / Toll-Free USA/Canada: +1 (888) 788-8955 Cautionary Statement This news release contains forward-looking statements relating to the future operations of Treatment and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the Offering, the use of proceeds of the Offering, the filing of a prospectus supplement and future plans and objectives of Treatment, are forward- looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from Treatment’s expectations include other risks detailed from time to time in the filings made by Treatment with securities regulators. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of Treatment. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking
Treatment.com AI and SPRYT Join Forces to Improve Patient Access to Healthcare Services
SPRYT has developed an AI receptionist called Asa – Medical Office Assistant (MOA) in your pocket Patients communicate with Asa via standard messaging apps such as WhatsApp and SMS/RCS. No app download required 25% of healthcare spending in the USA stems from administrative tasks such as billing and scheduling. This is over $1Trillion/yr Cost of missed appointments in the US alone is $150 Billion/yr Combining with Treatment AI’s Global Library of Medicine will look to create one of the world’s first AI powered patient onboarding and triaging tools at the time of booking VANCOUVER, British Columbia, September 17th, 2024 – Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (“Treatment”) is pleased to announce it has signed a Collaborative Agreement with SPRYT Limited (“SPRYT”). Both innovative AI healthcare organizations, SPRYT and Treatment are exploring complementary technology synergies, including Treatment’s proprietary Global Library of Medicine (“GLM”), to build new solutions designed to mitigate patient access challenges, administrative overheads for healthcare professionals and cost inefficiencies throughout our healthcare systems. According to McKinsey, of nearly $4 Trillion spent on healthcare annually in the United States, administrative spending is about one-quarter of the total i.e. $1Trillion/yr* How to reduce administrative spending in US healthcare | McKinsey Treatment is partnering with SPRYT, an innovative AI healthcare technology company, who has built an intelligent AI Medical Office Assistant (MOA), Asa. Asa enables patients to book, change and pay for appointments via instant message (WhatsApp/iMessage/SMS), predicts no-shows, and provides personalized language to encourage attendance at preventative healthcare appointments. SPRYT has already announced partnerships within the UK National Health Service (NHS). SPRYT is the first company to be approved to integrate a solution using WhatsApp and AI for scheduling to a NHS Electronic Health Record (EHR). Patient’s can interact with Asa like they would with a human MOA. The cost of missed medical appointments in the US alone is estimated at $150 Billion/yr* The Cost of Missed Medical Appointments: A Hidden Burden on Healthcare – TransLoc SPRYT incorporates behavioral science and applies generative AI to adjust language and messaging to specific population segments to help improve equitable access and optimize attendance at appointments, through predicting and reducing “no shows”. Treatment’s Global Library of Medicine (GLM) enables healthcare professionals to capture a patient’s presenting symptoms, past medical history and through smart proprietary algorithms, formulate the most likely diagnosis and suggest the most important tests/exams that should be performed. This history can then be shared with the patient’s healthcare professional in real time and also programmed to help with triaging patients more efficiently. Treatment and SPRYT intend to explore mutually beneficial opportunities through the partnership, including within the UK, North America and Middle East where both companies have already made inroads. The collaboration also allows SPRYT and Treatment to work closely on testing and developing further new mutual joint commercial applications and/or solutions. The intent of this collaboration is to utilize AI and both company’s respective technical and platform strengths, to eventually commercialize one or more solutions, which help with cost reductions for healthcare system payers, streamline inefficient processes and most importantly deliver better support and engagement for patients and healthcare professionals alike. Dr. Essam Hamza, CEO of Treatment.com AI, comments: “ We are very excited about this new collaboration with SPRYT which already has a foothold in the UK and is making inroads around the world, including the Middle East and USA. The intent of this collaboration is to create an AI powered solution that not only reduces missed appointments, but also takes a full medical history and helps efficiently triage patients, all from the comfort of their home or office. This has the promise to improve access and outcomes for patients, reduce costs for payers, and greatly reduce administrative burdens and costs for healthcare providers.” Daragh Donohue, Founder and CEO of SPRYT comments: ”We are delighted to be collaborating with Treatment.com. By combining our AI receptionist Asa, which acts as a front door to the healthcare system, with Treatment.com’s technology that takes a full medical history and helps triage patients, we can significantly improve patient experience while reducing admin burden within healthcare systems. Patients today face a complex and overburdened healthcare sector, and this partnership allows us to leverage our complementary technologies to create a more accessible, efficient, and patient-centric healthcare ecosystem.” Further, the Company announces that the Company has engaged Interactive Media Group of Texas, USA (“IMG”) to conduct a marketing awareness program for the Company for a period of one (1) month commencing on September 24, 2024, in consideration of a payment of USD$23,000. IMG does not currently own any interest, directly or indirectly, in the Company or its securities. About Treatment.com AI Inc. Treatment.com AI is a company utilizing AI and best clinical practices to positively disrupt the healthcare sector and impact current inefficiencies and challenges. Over the past 7+ years and with the input of hundreds of healthcare professionals globally, Treatment has built a comprehensive, personalized healthcare AI engine, the Global Library of Medicine (GLM). Providing highly qualified clinical information and support to all healthcare professionals, the GLM delivers >92%+ accuracy on first diagnosis as well as providing recommended tests (physical and lab), x-rays, and billing codes. The GLM helps healthcare professionals (doctor, nurse or pharmacist) reduce their administrative burden; create more time for needed face to face patient appointments and has the propensity for greater consistency in quality of patient support. Treatment also focuses on the next generation of healthcare professionals supporting Medical and Nursing schools, utilizing the GLM to help enhance the practical clinical skills of their students. Treatment’s GLM platform also brings the possibility of health equity and inclusion for disenfranchised communities. To learn more about Treatment’s products and services: www.treatment.com or email: info@treatment.com About SPRYT SPRYT is a healthcare technology company focused on improving appointment attendance and reducing operational inefficiencies in healthcare. SPRYT has developed an AI receptionist, Asa, that offers patients the convenience of managing and paying for their appointments via WhatsApp/RCS/SMS at any time, interacting as they
Treatment.com AI and University of Edinburgh Join Forces to Transform Long-Term Care Services across the UK
Collaboration with World Leading University, University of Edinburgh Multi-Million Dollar Transformative Project for Long-Term Care Future Partnering Opportunities VANCOUVER, British Columbia, September 5th, 2024 – Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (“Treatment”) is pleased to announce it has signed a Collaborative Agreement with the University Court of the University of Edinburgh (“University of Edinburgh”). The University of Edinburgh is looking to utilize Treatment’s proprietary Global Library of Medicine (“GLM”) to jointly build applications within the “SET4 Systems Engineering to Transform Transitions In Health and Social Care innovation initiative” (“SET4”). World Leading University Treatment is partnering with the University of Edinburgh, recently acknowledged as amongst the world’s top universities by The Times Higher Education Impact Rankings for its contribution to the UN’s Sustainable Development Goals. In the 2024 rankings, the University of Edinburgh achieved joint 1st in the world for SDG 9: Industry, Innovation and Infrastructure. Edinburgh Innovations, the University of Edinburgh’s commercialisation service, has attracted £107.6m (USD$142m) of investment, whilst industrial and translational research projects have brought in a further £91.9m (USD$121m) of funding. Multi-Million Dollar Transformative Project for Long-Term Care SET4 is an exciting multi-million dollar programme under development in the Usher Institute within the College of Medicine and Veterinary Medicine at the University of Edinburgh. It represents an innovation hub initiative including all relevant stakeholders, designed to deliver innovative data-driven solutions which improve problematic transitions in health and social care for people living within Multiple Long Term Conditions (MLTC). Whilst initially focused on specific communities in Scotland, the goal now is to deliver meaningful change with sufficient evidence to enable wider adoption across the UK National Health Service (NHS), other social care settings and beyond. Further Opportunities Beyond SET4, the parties will also work together to explore other relevant collaborative and commercial opportunities to positively impact healthcare system efficiency and enhanced care for patients. Kevin Peterson MD, MPH, FRCS(Ed), FAAFP, Chairman and Chief Medical Officer of Treatment.com AI says: “As a global leading university for industry and innovation, the University of Edinburgh provides a powerful academic partner for Treatment AI in our mission to improve clinical care using artificial intelligence. We are delighted and proud to work with Edinburgh Innovations to discover new ways of improving the lives of people initially in Scotland and subsequently across the world.” Julie Jacko Ph.D., Dean of Innovation and Engagement for the College of Medicine and Veterinary Medicine at University of Edinburgh comments: “Catalysing the transformation of health in UK society and globally is central to the mission of the Usher Institute. By prioritising people, populations and their data, the Usher Institute is at the forefront of discovery and innovation. Our partnership with Treatment.com AI will amplify the impact of our work, ensuring that health and wellbeing is improved for generations to come.” Further, the Company announces that it has amended the marketing/investor relations agreement with LEIT Media Ltd. (“LEIT”), as previously announced by the Company on July 2, 2024. Pursuant to the amended agreement, Treatment will provide an additional amount of 250,000 Euro to LEIT for the marketing campaign and the campaign will continue to focus on the German speaking investor community. About Treatment.com AI Inc. Treatment.com AI is a company utilizing AI and best clinical practices to positively disrupt the healthcare sector and impact current inefficiencies and challenges. Over the past 7+ years and with the input of hundreds of healthcare professionals globally, Treatment has built a comprehensive, personalized healthcare AI engine, the Global Library of Medicine (GLM). Providing highly qualified clinical information and support to all healthcare professionals, the GLM delivers >92%+ accuracy on first diagnosis as well as providing recommended tests (physical and lab), x-rays, and billing codes. The GLM helps healthcare professionals (doctor, nurse or pharmacist) reduce their administrative burden; create more time for needed face to face patient appointments and has the propensity for greater consistency in quality of patient support. Treatment also focuses on the next generation of healthcare professionals supporting Medical and Nursing schools, utilizing the GLM to help enhance the practical clinical skills of their students. Treatment’s GLM platform also brings the possibility of health equity and inclusion for disenfranchised communities. To learn more about Treatment’s products and services, please email: info@treatment.com About University of Edinburgh/Edinburgh Innovations The University of Edinburgh is a global university, rooted in Scotland. We are globally recognised for our research, development and innovation and we have provided world-class teaching to our students for more than 425 years. We are the largest university in Scotland, with more than 49,480 students and 18,650 staff. We are a founding member of the UK’s Russell Group of leading research universities and a member of the League of European Research Universities. Edinburgh Innovations is the University of Edinburgh’s commercialisation service. We bring University of Edinburgh research to industry, working to identify ideas with value, and facilitating the process of bringing them to life in real-world applications. We make ideas work for a better world. Find out more on our website Contact: If you would like to find out more about Edinburgh University’s innovation and engagement initiatives, please contact: Megan Welford, Communications Manager, Edinburgh Innovations, megan.welford@ei.ed.ac.uk ; Call: + 44 7721 120217. FOR ADDITIONAL INFORMATION, CONTACT: Dr. Essam Hamza, CEO ehamza@treatment.com If you would like to find out more about Treatment’s products and services, please email at info@treatment.com For media inquiries, contact: media@treatment.com Call: +1 (612) 788-8900 / Toll-Free USA/Canada: +1 (888) 788-8955 Cautionary Statements This news release contains forward-looking statements that are based on Treatment.com AI’s expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to the implementation of its shareholder communications initiative and the timing thereof. Although Treatment.com believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements, and readers should
Treatment.com AI – Revolutionizing Healthcare: Harnessing the Power of AI for Transformative Patient Care
VANCOUVER, British Columbia, August 21, 2024 – Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (“Company” or “Treatment”), a healthcare tech company transforming patient care with AI-driven clinical insights, endorses the forward thinking emanating from a recent event in Washington comprising 25 of the nation’s leading experts on the appropriate use of artificial intelligence (AI) within healthcare. It is understood there are real challenges to the stability and sustainability of our present day healthcare systems: shortages of healthcare professionals; administrative overload; disenfranchised communities with little or no access to healthcare professionals, long wait times for general practitioners and specialists, and time pressures on healthcare professionals in being able to spend sufficient time with patients. Some of the excellent thinking and recommendations from the article published by UW School of Medicine and Public Health on July 29th Roundtable on AI in Healthcare produces key recommendations | News | UW Health included: Utilizing AI to help alleviate healthcare workforce burdens and improving efficiency and patient outcomes Technology, policy and compensatory models for healthcare professionals need to align for AI to effectively impact healthcare systems Equitable access for patients and care teams AI in healthcare is effectively governed Treatment’s comprehensive and integrated online medical library powered by AI – Global Library of Medicine (GLM), which utilizes proprietary algorithms, was designed to impact many of these challenges. At its heart, the GLM provides some of the highest levels of qualified clinical support to many healthcare professionals, ensuring enhanced diagnostic accuracy and transparency in every step of support provided. It is contained within a “closed” environment which can sit securely behind organizational firewalls, but most importantly enables Large Language Models (LLM’s) such as Chat GPT to query trusted content. This helps LLM’s reduce chances of misdiagnosis, bias, hallucinations and/or possible IP infringements. Further, as outlined above, with the challenges facing our healthcare systems, the GLM has been designed to help mitigate many of today’s menial tasks for healthcare professionals such as history taking, typing chart notes, billing and ensuring they are spending quality face time with patients who need to be seen. In turn, this will have a positive impact on costs and cost allocation for Healthcare organizations and governing bodies. Dr, Essam Hamza, CEO Treatment.com AI comments: “We applaud the hard work of the thought leaders in this space including from this Roundtable. The outcomes of this event and others further demonstrate that Treatment AI is on the right track with its commitment to supporting all the healthcare stakeholders. We strive to reduce workload for healthcare Professionals, help improve efficiency for the Payers, and enhance accuracy and accessibility for the Patients. We look forward to updating the market on new products, partnerships and developments over the next few months. ” About Treatment.com AI Inc. Treatment.com AI is a company utilizing AI to positively disrupt the healthcare sector and impact current inefficiencies and challenges. Over the past 7+ years and with the input of hundreds of healthcare professionals globally, Treatment.com AI has built the world’s most intelligent, personalized healthcare AI engine, the Global Library of Medicine (GLM). Providing the highest qualified clinical information and support to all healthcare professionals, the GLM delivers >92%+ accuracy on first diagnosis as well as providing recommended tests (physical and lab), x-rays, and billing codes. The platform’s quality and transparency are unrivaled, as the GLM provides an explanation of every step and likelihood associated with every symptom. Treatment.com AI also focuses on the next generation of healthcare professionals supporting Medical and Nursing schools, who utilize the GLM to help enhance the future clinical skills of their students. Treatment.com AI is focused on using AI for good and utilizing its GLM platform to bring the possibility of health equity and inclusion for disenfranchised communities. FOR ADDITIONAL INFORMATION, CONTACT: Dr. Essam Hamza, CEO ehamza@treatment.com If you would like to find out more about Treatment’s products and services, please email at info@treatment.com For media inquiries, contact: media@treatment.com Call: +1 (612) 788-8900 / Toll-Free USA/Canada: +1 (888) 788-8955 Cautionary Statements This news release contains forward-looking statements that are based on Treatment.com AI’s expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to the implementation of its shareholder communications initiative and the timing thereof. Although Treatment.com believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements, and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and Treatment.com undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.
Treatment.com AI announces AI Pharmacy Assistant
VANCOUVER, British Columbia, July 31, 2024 – Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (“Company” or “Treatment”), a healthcare tech company transforming patient care with AI-driven clinical insights is excited to announce a new solution, AI Pharmacy Assistant designed to support pharmacists. Pharmacists are playing an increasing role in the provision of clinical decision support services, given the increasing number of people without a GP and/or the time taken to book appointments. As one example, the Ontario government recently announced pharmacies provided over 1 million assessments for common ailments since last year Ontario Exploring More Ways to Expand Role of Pharmacists | Ontario Newsroom. This is representative of similar trends being seen across Canada, UK and emerging legislation in the US, all of which will lead to extending the role for pharmacists within the healthcare continuum of care. Globally, pharmacists will play a significant role in alleviating the shortages of healthcare professionals, timeliness of patient support and mitigating the financial pressures prevalent in today’s healthcare systems. For many people, especially in underserved communities, the pharmacist is often the only healthcare professional people see. Therefore, providing these pharmacists with the tools and confidence to administer a wider range of services, has a positive impact for them and the wellbeing of their communities. Working with pharmacists, Treatment is excited to be announcing its new AI Pharmacy Assistant solution for pharmacists, expected to launch later in 2024. The solution is underpinned by Treatment’s AI powered proprietary Global Library of Medicine (GLM), the most comprehensive and integrated online medical library. The GLM has been created with hundreds of credentialled clinicians globally to ensure the highest qualified clinical information and support to all healthcare professionals. AI Pharmacy Assistant will be either accessible on a patient’s mobile device or through a kiosk tablet at the pharmacy. It will support pharmacists in multiple ways: Reducing the time to take patient histories and symptoms using Treatment’s GLM Automatically document all interactions with patients providing an audit trail Extending confidence and support in expanded diagnostic support provided to patients Minimize the risk of errors and increase clinical efficiency Providing comprehensive diagnostic and symptom information backed by the most reliable and up-to-date medical research The global clinical decision support systems (CDSS) market is projected to grow significantly, reaching approximately $4.05 billion by 2029 from $2.46 billion in 2024, driven by technological advancements and the integration of AI and machine learning in healthcare decision-making processes. Whilst there is a clear desire to expand the pharmacist’s scope of practice, there is also a huge shortage of pharmacists globally. Therefore, pharmacists are being stretched at both ends: more work, less staff. Supportive and accurate support tools which can be trusted, such as Treatment’s AI Pharmacy Assistant, will be a pivotal part of the solution. Dr. Essam Hamza, CEO of Treatment.com AI, comments: “We are excited to announce another new product line and revenue stream for our GLM platform. We have been working closely with industry professionals and government agencies to ensure we create a valuable tool that will have the most immediate impact for all the stakeholders. For Payers, we help improve efficiency and hopefully avoid patient complications and unneeded costly hospital visits. For the Pharmacists, we help relieve administrative headaches and give them comfort to see more patients. Finally, and most importantly, for the Patient, we provide more and better access to care for themselves and their family members.” About Treatment.com AI Inc. Treatment.com AI is a company utilizing AI to positively disrupt the healthcare sector and impact current inefficiencies and challenges. Over the past 7+ years and with the input of hundreds of healthcare professionals globally, Treatment.com AI has built the world’s most intelligent, personalized healthcare AI engine, the Global Library of Medicine (GLM). Providing the highest qualified clinical information and support to all healthcare professionals, the GLM delivers >92%+ accuracy on first diagnosis as well as providing recommended tests (physical and lab), x-rays, and billing codes. The platform’s quality and transparency are unrivaled, as the GLM provides an explanation of every step and likelihood associated with every symptom. Treatment.com AI also focuses on the next generation of healthcare professionals supporting Medical and Nursing schools, who utilize the GLM to help enhance the future clinical skills of their students. Treatment.com AI is focused on using AI for good and utilizing its GLM platform to bring the possibility of health equity and inclusion for disenfranchised communities. FOR ADDITIONAL INFORMATION, CONTACT: Dr. Essam Hamza, CEO ehamza@treatment.com If you would like to find out more about Treatment’s products and services, please email at info@treatment.com For media inquiries, contact: media@treatment.com Call: +1 (612) 788-8900 / Toll-Free USA/Canada: +1 (888) 788-8955 Cautionary Statements This news release contains forward-looking statements that are based on Treatment.com AI’s expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to the implementation of its shareholder communications initiative and the timing thereof. Although Treatment.com believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements, and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and Treatment.com undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.
Treatment.com AI Provides an Update on the Status of Exercised Warrants
~800,000 warrants exercised since free trading was announced raising close to half a million dollars. Remaining warrants could bring over $2 million in additional funds. Robust acquisition pipeline VANCOUVER, British Columbia, July 24th, 2024 – Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (the “Company” or “Treatment”), a healthcare tech company transforming patient care with AI-driven clinical insights is pleased to provide the market with an update on the exercising of the warrants which were issued upon conversion of the special warrants on June 21, 2024. Since the special warrant conversion, the Company is thrilled to announce that almost 800,000 warrants have been exercised raising gross proceeds approximating to half a million dollars. Dr. Essam Hamza, CEO of Treatment.com AI, comments: “These warrant exercises underscore the strong investor support for our company. The cash injection enables us to expedite our plans at a time when both the investor and healthcare markets are looking for credible AI solutions to mitigate the challenges faced by our healthcare systems. Apart from our previously announced plans to launch our “AI Patient” and “AI Doctor in the Pocket” products this fall, we also have a strong acquisition pipeline under review that could provide an accelerated timeline for our growth strategy. We look forward to the exercising of the remaining warrants which could bring another $2 Million injection to the treasury”. About Treatment.com AI Inc. Treatment.com AI is a company utilizing AI to positively disrupt the healthcare sector and impact current inefficiencies and challenges. Over the past 7+ years and with the input of hundreds of healthcare professionals globally, Treatment.com AI has built the world’s most intelligent, personalized healthcare AI engine, the Global Library of Medicine (GLM). Providing the highest qualified clinical information and support to all healthcare professionals, the GLM delivers >92%+ accuracy on first diagnosis as well as providing recommended tests (physical and lab), x-rays, and billing codes. The platform’s quality and transparency are unrivaled, as the GLM provides an explanation of every step and likelihood associated with every symptom. Treatment.com AI also focuses on the next generation of healthcare professionals supporting Medical and Nursing schools, who utilize the GLM to help enhance the future clinical skills of their students. Treatment.com AI is focused on using AI for good and utilizing its GLM platform to bring the possibility of health equity and inclusion for disenfranchised communities. FOR ADDITIONAL INFORMATION, CONTACT: Dr. Essam Hamza, CEO ehamza@treatment.com If you would like to find out more about Treatment’s products and services, please email at info@treatment.com For media inquiries, contact: media@treatment.com Call: +1 (612) 788-8900 / Toll-Free USA/Canada: +1 (888) 788-8955 Cautionary Statements This news release contains forward-looking statements that are based on Treatment.com AI’s expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to the implementation of its shareholder communications initiative and the timing thereof. Although Treatment.com believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements, and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and Treatment.com undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.
Treatment.com AI Provides Latest Corporate Update
Positive Financial Update New Partnerships Announced – aiXplain/Novus Health GLM – AI Accuracy and Effectiveness in Healthcare Bolstering the Executive, Scientific and Development Team – Dr. Jean Challiner AI Patient and AI Doctor in Your Pocket planned release in H2 VANCOUVER, British Columbia, July 9th, 2024 – Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (the “Company” or “Treatment AI”) is pleased to provide a general corporate update. Treatment AI has been working diligently through Q1 and Q2 to ensure continued evolution of its platform (Global Library of Medicine or GLM) and strengthening its pipeline for new business and partnerships. A few key milestones the Company has accomplished include: Financial Update On March 13, 2024, the company completed an oversubscribed non-brokered private placement of 6,295,500 special warrants and 975,000 units issued at $0.40 each for aggregate gross proceeds of $2,908,200. Each unit consists of one share and one-half of one warrant. Each whole warrant is exercisable for one share at the strike price of $0.60 for a period of two years. We are pleased to report that on June 21, 2024, the special warrants converted to free trading units. The Company is also pleased to announce that it is now debt free, having closed a debt settlement transaction with arm’s-length creditors in March, 2024 settling an aggregate amount of $461,307.40 in debt and the recently announced debt settlement transaction on June 27, 2024, whereby the Company shall settle an additional $650,000 in debt with arm’s-length creditors, which is anticipated to close in the near term. Dr. Essam Hamza, CEO states “We are very appreciative of the strong investor support for our company. This is a critical inflection point for the company, the significant infusion of cash is helping expedite the tremendous commercial opportunity in front of us. We also look forward to the exercising of the warrants which could bring another over $2 Million to the treasury”. New Partnerships Announced Treatment AI recently announced two new partnerships with aiXplain and Novus Health. aiXplain: Enables greater access to Treatment AI’s proprietary Global Library of Medicine (“GLM”) by contributing to aiXplain’s ever-growing dynamic Artificial Intelligence (AI) marketplace. The collaboration also allows aiXplain and Treatment AI to work closely on testing and the development of further new mutual joint commercial applications and/or solutions for a global market. Novus Health: An acknowledged leader in health navigation supporting over 1.5 million members and their families. Novus Health works with a number of leading North American Health Insurers and has built a trusted navigation platform that simplifies health care experiences by bringing together everything an individual needs to successfully manage their care journey. Treatment AI and Novus Health are looking to collaborate to build out new and differentiated solutions for the Health Risk Assessment and Medical Second Opinion markets. GLM – Further Validation of Treatment AI’s Accuracy and Effectiveness While reservations persist in how AI can be meaningfully and safely used in healthcare, Treatment AI continues to demonstrate the platform’s accuracy and effectiveness. Treatment AI recently conducted a trial where a student, using our platform, successfully examined 12 test patients under OSCE conditions. The Objective Structured Clinical Examination (“OSCE”), is a standard clinical exam of diagnostic aptitude at medical and nursing schools in 57 countries globally. The student, without any prior medical training, entered basic patient information and followed Treatment’s AI platform guided prompts to complete individualized assessments. The student then wrote clinical notes summarizing findings and suggested diagnoses. The results were impressive, with the student achieving an accuracy rate of >92% (11 of 12 cases) in diagnosing complex conditions, including colon cancer, appendicitis, acute myocardial infarction, diabetes, and patellar tendonitis. These results are significantly above results expected from medical students taking the same examinations. Bolstering the Executive, Scientific and Development Team Richard Atkins – Appointed Chief Operating Officer Mr. Atkins brings to the business a successful career with over 30 years’ experience in international sales, partnerships, executive management and M&A, highlighted by multiple multi-million dollar deals working with both major health-tech and software corporations. Mr. Atkins spent his formative career in software and technology including: networking, managed services, data centers & virtualization, omnichannel contact centers, CRM, enterprise search/ data analytics, cloud-based applications. However, for the past 15 years, he has brought his experience to healthcare, working across the continuum of care, with a focus on clinical decision support. His experience spans innovative international physical and mental health solutions including:- (i) Digital Health – healthbots, symptom checkers, telehealth, Alexa voice and social media solutions (ii) National/Provincial teletriage services (iii) Managed PACS/RIS and LIM services in both public/private sectors (iv) EMR/Billing and HL7/FHIR interoperability. Dr. Jean Challiner – Executive Advisor Dr. Challiner is a globally acknowledged expert in clinical decision support. As a doctor with a wealth of clinical experience, Dr. Challiner has helped pioneer specialized technology enabling the delivery of healthcare services since 2002, with a focus on the highest quality of clinical governance. Dr. Challiner’s career began as a General Practitioner, moving to Accident & Emergency with a particular interest in pre-hospital care. Dr Challiner received a fellowship in Immediate Medical Care from the Faculty of Pre Hospital Care at the University of Edinburgh, Scotland in 2001. For more than 20 years, Dr. Challiner has held Executive positions, including Medical Director or Executive Director roles with both public bodies (including the UK National Health Service (NHS), one of the world’s pre-eminent healthcare systems) and commercial organizations, as well as advisory roles with several early-stage companies. Dr. Challiner’s responsibilities have encompassed clinical decision support constructs, governance and clinical safety. Dr. Challiner’s work with organizations globally has helped them transform local and national healthcare services and patient self assessment in countries as diverse as the UK, US, Australia, New Zealand, Portugal, Scandinavia, Brazil and Ghana. Given her experience with both national pandemic projects and public health alerts (including Swine Flu; Legionnaires disease; UK Polonium incident and Ebola outbreak in Africa), Dr. Challiner was recently included in the NHS COVID pandemic Governance Team. Aligning with Treatment
Treatment.com AI Engages IR Service Provider
VANCOUVER, British Columbia, July 2, 2024 – Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (“Treatment”) has engaged Leit Media Ltd. (“Leit”) of London, UK, to provide investor relations and marketing services with a focus on the German stock market and the German-speaking investor community for an initial period of six months commencing July 1, 2024, in consideration of EUR 250,000, and pursuant to an agreement dated July 1, 2024. Leit does not currently own any interest, directly or indirectly, in the Company or its securities.About Treatment.com AI Inc. Treatment.com AI is a company utilizing AI to positively disrupt the healthcare sector and impact current inefficiencies and challenges. Over the past 7+ years and with the input of hundreds of healthcare professionals globally, Treatment.com AI has built the world’s most intelligent, personalized healthcare AI engine, the Global Library of Medicine (GLM). Providing the highest qualified clinical information and support to all healthcare professionals, the GLM delivers >92%+ accuracy on first diagnosis as well as providing recommended tests (physical and lab), x-rays, and billing codes. The platform’s quality and transparency are unrivaled, as the GLM provides an explanation of every step and likelihood associated with every symptom. Treatment.com AI also focuses on the next generation of healthcare professionals supporting Medical and Nursing schools, who utilize the GLM to help enhance the future clinical skills of their students. Treatment.com AI is focused on using AI for good and utilizing its GLM platform to bring the possibility of health equity and inclusion for disenfranchised communities. FOR ADDITIONAL INFORMATION, CONTACT: Dr. Essam Hamza, CEO ehamza@treatment.com If you would like to find out more about Treatment’s products and services, please email at info@treatment.com For media inquiries, contact: media@treatment.com Call: +1 (612) 788-8900 / Toll-Free USA/Canada: +1 (888) 788-8955 Cautionary Statements This news release contains forward-looking statements that are based on Treatment.com AI’s expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to the implementation of its shareholder communications initiative and the timing thereof. Although Treatment.com believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements, and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and Treatment.com undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.
Treatment.com AI and Novus Health Partnership Expands Access to its Global Library of Medicine (GLM)
VANCOUVER, British Columbia, May 15, 2024 – Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (“Treatment”) is pleased to announce it has signed a Collaborative Agreement with Health Care Services International Inc (o/a Novus Health). (“Novus Health”) to explore utilization of Treatment’s proprietary Global Library of Medicine (“GLM”) to further enhance Novus Health’s Health Risk Assessment programs. Treatment is partnering with Novus Health, an acknowledged leader in health navigation supporting over 1.5 million members and their families. Over the past 7 years and in collaboration with hundreds of global healthcare professionals, utilizing our proprietary algorithms, Treatment has built one of the world’s most intelligent, personalized healthcare AI engines, the Global Library of Medicine (GLM). Working with a number of leading North American Health Insurers, Novus Health has built a trusted navigation platform that simplifies health care experiences by bringing together everything an individual needs to successfully manage their care journey. Treatment and Novus Health also intend to explore mutually beneficial opportunities through the partnership, this will include Health Risk Assessment and Medical Second Opinion. The collaboration also allows Novus Health and Treatment to work closely on testing and development of further new mutual joint commercial applications and/or solutions. The intent of this collaboration is to promote the development, installation, testing, validation, and commercialization of one or more novel solutions that further the goals of both companies and proactively impact the health insurance market. Dr. Essam Hamza, CEO of Treatment, comments: “We are very excited to partner with a recognized leading healthcare firm in Novus Health. There is a near term opportunity to implement our proprietary AI diagnostic tools into the solutions offered to their vast customer base. However, with this collaboration we also have an opportunity to extend into new mutually developed tools and solutions that have the ability to further improve health care efficiency and patient outcomes.” Jamie Marcellus, CEO of Novus Health, comments: “We are excited about the potential for Treatment.com’s AI to augment our services. Their platform offers the possibility of unparalleled efficiency and accuracy in health risk assessments, drawing insights from vast data sets to detect patterns and predict potential risks. By leveraging these tools, our members can make better informed decisions swiftly, enhancing care and enabling proactive interventions to mitigate health threats effectively.” About Treatment.com AI Inc. Treatment.com AI is a company utilizing AI to positively disrupt the healthcare sector and impact current inefficiencies and challenges. Over the past 7+ years and with the input of hundreds of healthcare professionals globally, Treatment.com AI has built the world’s most intelligent, personalized healthcare AI engine, the Global Library of Medicine (GLM). Providing the highest qualified clinical information and support to all healthcare professionals, the GLM delivers >92%+ accuracy on first diagnosis as well as providing recommended tests (physical and lab), x-rays, and billing codes. The platform’s quality and transparency are unrivaled, as the GLM provides an explanation of every step and likelihood associated with every symptom. Treatment.com AI also focuses on the next generation of healthcare professionals supporting Medical and Nursing schools, who utilize the GLM to help enhance the future clinical skills of their students. Treatment.com AI is focused on using AI for good and utilizing its GLM platform to bring the possibility of health equity and inclusion for disenfranchised communities. About Novus Health Novus Health connects people with care and is a leader in health navigation. We deliver personalized support, reputable information, and health-related services in one single destination, using technology to help individuals make informed health decisions. In doing so, we create value for our partners while improving their members’ and customers’ health and well-being. To learn more, visit www.novushealth.com Contact: Jamie Marcellus, CEO jmarcellus@novushealth.com If you would like to find out more about Novus Health’s products and services, please email at info@novushealth.com FOR ADDITIONAL INFORMATION, CONTACT: Dr. Essam Hamza, CEO ehamza@treatment.com If you would like to find out more about Treatment’s products and services, please email at info@treatment.com For media inquiries, contact: media@treatment.com Call: +1 (612) 788-8900 / Toll-Free USA/Canada: +1 (888) 788-8955 Cautionary Statements This news release contains forward-looking statements that are based on Treatment.com AI’s expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to the implementation of its shareholder communications initiative and the timing thereof. Although Treatment.com believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements, and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and Treatment.com undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.